351
|
Forbat E, Al-Niaimi F, Ali FR. Use of nicotinamide in dermatology. Clin Exp Dermatol 2017; 42:137-144. [PMID: 28052374 DOI: 10.1111/ced.13021] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2016] [Indexed: 02/04/2023]
Abstract
Nicotinamide (niacinamide) is the water-soluble, amide form of vitamin B3. We review the evidence underlying the use of nicotinamide for various dermatological indications, including nonmelanoma cancer prophylaxis, blistering disorders, acne vulgaris and cosmetic indications, and speculate upon its future role in dermatological practice.
Collapse
Affiliation(s)
- E Forbat
- King Edward VII Hospital, London, UK
| | - F Al-Niaimi
- Dermatological Surgery and Laser Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, UK
| | - F R Ali
- Dermatological Surgery and Laser Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, UK
| |
Collapse
|
352
|
Lim HW, Arellano-Mendoza MI, Stengel F. Current challenges in photoprotection. J Am Acad Dermatol 2016; 76:S91-S99. [PMID: 28038886 DOI: 10.1016/j.jaad.2016.09.040] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Revised: 09/16/2016] [Accepted: 09/18/2016] [Indexed: 11/17/2022]
Abstract
Electromagnetic radiation in the ultraviolet, visible, and infrared ranges all produce biologic effects. Ultraviolet filters are the most well-studied photoprotective measure for the adverse effects of ultraviolet radiation. Because of the reported endocrinologic effects of oxybenzone in animal studies, its effects on coral reefs, and its photocontact allergy potential, its use has been minimized in many countries worldwide. New developments in topical antioxidants and oral and subcutaneous agents (eg, Polypodium leucotomos extract, afamelanotide, nicotinamide) with photoprotective and antiphotocarcinogenic properties could potentially provide addition modalities for protection against the effects of visible light and infrared radiation.
Collapse
Affiliation(s)
- Henry W Lim
- Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.
| | | | | |
Collapse
|
353
|
Bostom AG, Merhi B, Walker J, Robinson-Bostom L. More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients. World J Transplant 2016; 6:658-664. [PMID: 28058215 PMCID: PMC5175223 DOI: 10.5500/wjt.v6.i4.658] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Revised: 10/03/2016] [Accepted: 11/02/2016] [Indexed: 02/05/2023] Open
Abstract
Non-melanoma cutaneous carcinomas, or skin cancers, predominantly squamous cell carcinomas (SCCs), are the most common malignancies occurring in kidney transplant recipients (KTRs). Squamous cell carcinoma risk is dramatically elevated in KTRs, occurring at rates of up 45-250 times those reported in general populations. New non-melanoma skin cancers in KTRs with a prior non-melanoma skin cancer also develop at 3-times the rate reported in non-KTRs with the same clinical history. The unique aggressiveness of SCCs in KTRs increases patient morbidity, due to the high rate of new lesions requiring treatment, frequently surgical excision. Oral nicotinamide shows promise in the chemoprevention of the especially aggressive non-melanoma skin cancers which occur in KTRs. This benefit might be conferred via its inhibition of sirtuin enzymatic pathways. Nicotinamide’s concurrent hypophosphatemic effect may also partially ameliorate the disturbed calcium-phosphorus homeostasis in these patients-a putative risk factor for mortality, and graft failure. Conceivably, a phase 3 trial of nicotinamide for the prevention of non-melanoma skin cancers in KTRs, lasting at least 12-mo, could also incorporate imaging and laboratory measures which assess nicotinamide’s impact on subclinical cardiovascular and chronic kidney disease risk, and progression.
Collapse
|
354
|
Mounessa J, Buntinx-Krieg T, Qin R, Dunnick CA, Dellavalle RP. Primary and Secondary Chemoprevention of Malignant Melanoma. Am J Clin Dermatol 2016; 17:625-634. [PMID: 27665299 DOI: 10.1007/s40257-016-0221-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The incidence of malignant melanoma (MM) continues to rise in the United States. While sun protection and full body skin examinations remain the mainstay of preventative care, chemoprevention of the deadly disease has become an increasingly popular field of study. In this focused review, we discuss current findings and analyze the risks and benefits of various agents investigated for the primary and secondary chemoprevention of MM. Such agents include topical retinoids, vitamins, and supplements, Polypodium leucotomas extracts, non-steroidal anti-inflammatory agents (NSAIDs), statins, sunscreens, and field therapy with topical imiquimod for primary and secondary chemoprevention. We further identify a need for expanded high quality human research on the topic.
Collapse
Affiliation(s)
- Jessica Mounessa
- Stony Brook University School of Medicine, 101 Nicolls Road, Stony Brook, NY, 11794, USA
- Department of Dermatology, University of Colorado Hospital, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - Talayesa Buntinx-Krieg
- University of Central Florida College of Medicine, 6850 Lake Nona Blvd, Orlando, FL, 32827, USA
| | - Rosie Qin
- Department of Medicine, University of San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA
| | - Cory A Dunnick
- Department of Dermatology, University of Colorado Hospital, 1665 Aurora Ct, Aurora, CO, 80045, USA
- Department of Dermatology, Denver VA Medical Center, 1055 Clermont St. #165, Denver, CO, 80220, USA
| | - Robert P Dellavalle
- Department of Dermatology, University of Colorado Hospital, 1665 Aurora Ct, Aurora, CO, 80045, USA.
- Department of Dermatology, Denver VA Medical Center, 1055 Clermont St. #165, Denver, CO, 80220, USA.
| |
Collapse
|
355
|
Lenglet A, Liabeuf S, Bodeau S, Louvet L, Mary A, Boullier A, Lemaire-Hurtel AS, Jonet A, Sonnet P, Kamel S, Massy ZA. N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. Toxins (Basel) 2016; 8:toxins8110339. [PMID: 27854278 PMCID: PMC5127135 DOI: 10.3390/toxins8110339] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 11/07/2016] [Accepted: 11/07/2016] [Indexed: 12/17/2022] Open
Abstract
N-methyl-2-pyridone-5-carboxamide (2PY, a major metabolite of nicotinamide, NAM) was recently identified as a uremic toxin. Recent interventional trials using NAM to treat high levels of phosphorus in end-stage renal disease have highlighted new potential uremic toxicities of 2PY. In the context of uremia, the accumulation of 2PY could be harmful-perhaps by inhibiting poly (ADP-ribose) polymerase-1 activity. Here, we review recently published data on 2PY's metabolism and toxicological profile.
Collapse
Affiliation(s)
- Aurélie Lenglet
- Institut National de la Santé et de la Recherche Médicale (INSERM U-1088), Jules Verne University of Picardie, Amiens 80000, France.
- Department of Pharmacy, Amiens University Medical Center, Amiens 80000, France.
| | - Sophie Liabeuf
- Institut National de la Santé et de la Recherche Médicale (INSERM U-1088), Jules Verne University of Picardie, Amiens 80000, France.
- Clinical Research Centre and Division of Clinical Pharmacology, Amiens University Medical Center, Amiens 80000, France.
| | - Sandra Bodeau
- Institut National de la Santé et de la Recherche Médicale (INSERM U-1088), Jules Verne University of Picardie, Amiens 80000, France.
- Laboratory of Pharmacology and Toxicology, Amiens University Medical Center, Amiens 80000, France.
| | - Loïc Louvet
- Institut National de la Santé et de la Recherche Médicale (INSERM U-1088), Jules Verne University of Picardie, Amiens 80000, France.
| | - Aurélien Mary
- Institut National de la Santé et de la Recherche Médicale (INSERM U-1088), Jules Verne University of Picardie, Amiens 80000, France.
- Department of Pharmacy, Amiens University Medical Center, Amiens 80000, France.
| | - Agnès Boullier
- Institut National de la Santé et de la Recherche Médicale (INSERM U-1088), Jules Verne University of Picardie, Amiens 80000, France.
- Biochemistry Laboratory, Amiens University Medical Center, Amiens 80000, France.
| | | | - Alexia Jonet
- Laboratory of Glycochimie, des Antimicrobiens et des Agroressouces, Unité Mixte de Recherche-Centre National de la Recherché Scientifique (UMR CNRS) 7378, UFR de Pharmacy, Jules Verne University of Picardie, Amiens 80000, France.
| | - Pascal Sonnet
- Laboratory of Glycochimie, des Antimicrobiens et des Agroressouces, Unité Mixte de Recherche-Centre National de la Recherché Scientifique (UMR CNRS) 7378, UFR de Pharmacy, Jules Verne University of Picardie, Amiens 80000, France.
| | - Said Kamel
- Institut National de la Santé et de la Recherche Médicale (INSERM U-1088), Jules Verne University of Picardie, Amiens 80000, France.
- Biochemistry Laboratory, Amiens University Medical Center, Amiens 80000, France.
| | - Ziad A Massy
- Division of Nephrology, Ambroise Paré University Medical Center, Assistance Publique-Hôpitaux de Paris APHP, Boulogne, Billancourt, Paris 92100, France.
- INSERM U1018, Team 5, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Paris-Saclay University, and Paris Ouest-Versailles-Saint-Quentin-en-Yvelines University (UVSQ), Villejuif 94800, France.
| |
Collapse
|
356
|
Matthews E, Dessent CEH. Locating the Proton in Nicotinamide Protomers via Low-Resolution UV Action Spectroscopy of Electrosprayed Solutions. J Phys Chem A 2016; 120:9209-9216. [DOI: 10.1021/acs.jpca.6b10433] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Edward Matthews
- Department of Chemistry, University of York, Heslington, York, YO10 5DD, U.K
| | | |
Collapse
|
357
|
Palanichamy K, Kanji S, Gordon N, Thirumoorthy K, Jacob JR, Litzenberg KT, Patel D, Chakravarti A. NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability. Clin Cancer Res 2016; 23:2325-2334. [PMID: 27810903 DOI: 10.1158/1078-0432.ccr-16-1323] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 09/19/2016] [Accepted: 10/12/2016] [Indexed: 12/12/2022]
Abstract
Purpose: To identify potential molecular hubs that regulate oncogenic kinases and target them to improve treatment outcomes for glioblastoma patients.Experimental Design: Data mining of The Cancer Genome Atlas datasets identified nicotinamide-N-methyl transferase (NNMT) as a prognostic marker for glioblastoma, an enzyme linked to the reorganization of the methylome. We tested our hypothesis that NNMT plays a crucial role by modulating protein methylation, leading to inactivation of tumor suppressors and activation of oncogenes. Further experiments were performed to understand the underlying biochemical mechanisms using glioblastoma patient samples, established, primary, and isogenic cells.Results: We demonstrate that NNMT outcompetes leucine carboxyl methyl transferase 1 (LCMT1) for methyl transfer from principal methyl donor SAM in biological systems. Inhibiting NNMT increased the availability of methyl groups for LCMT1 to methylate PP2A, resulting in the inhibition of oncogenic serine/threonine kinases (STK). Further, NNMT inhibition retained the radiosensitizer nicotinamide and enhanced radiation sensitivity. We have provided the biochemical rationale of how NNMT plays a vital role in inhibiting tumor suppressor PP2A while concomitantly activating STKs.Conclusions: We report the intricate novel mechanism in which NNMT inhibits tumor suppressor PP2A by reorganizing the methylome both at epigenome and proteome levels and concomitantly activating prosurvival STKs. In glioblastoma tumors with NNMT expression, activation of PP2A can be accomplished by FDA approved perphenazine (PPZ), which is currently used to treat mood disorders such as schizophrenia, bipolar disorder, etc. This study forms a foundation for further glioblastoma clinical trials using PPZ with standard of care treatment. Clin Cancer Res; 23(9); 2325-34. ©2016 AACR.
Collapse
Affiliation(s)
- Kamalakannan Palanichamy
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio.
| | - Suman Kanji
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio
| | - Nicolaus Gordon
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio
| | - Krishnan Thirumoorthy
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio
| | - John R Jacob
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio
| | - Kevin T Litzenberg
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio
| | - Disha Patel
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio
| | - Arnab Chakravarti
- Department of Radiation Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio
| |
Collapse
|
358
|
Escudero-Góngora M, Fernández-Peñas P. Nicotinamide: New Indications in Dermatology. ACTAS DERMO-SIFILIOGRAFICAS 2016. [DOI: 10.1016/j.adengl.2016.05.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
359
|
Abstract
BACKGROUND Basal cell carcinoma (BCC) is the most common skin cancer in fair-skinned individuals. Although lymph node or visceral metastases are observed in less than 0.5 % of all cases, BCC can have a fatal course due to its highly invasive growth pattern. OBJECTIVES To provide a comprehensive update on diagnosis, treatment, and prevention of BCC. MATERIALS AND METHODS We review the current literature and recommendations of the German guidelines on treatment and prevention of skin cancer. The most pertinent developments are summarized in this review article. RESULTS The use of optical coherence tomography and reflectance confocal microscopy can significantly improve the diagnosis of BCC compared with clinical assessment and dermoscopy alone. Mohs micrographic surgery remains the therapeutic gold standard for tumors in the head and facial area and tumors with high-risk features. The application of imiquimod, 5‑fluorouracil, or photodynamic therapy should be restricted to low-risk superficial tumors. Topical inhibitors of the sonic hedgehog (SHH) pathway are currently being evaluated in early clinical trials. In contrast, vismodegib and sonidegib have been approved for the systemic treatment of locally advanced and metastatic BCC with good response rates. The most common adverse events of both agents are muscle cramps, dysgeusia, diffuse alopecia, weight loss, and fatigue. In an Australian phase III trial, oral nicotinamide (vitamin B3) reduced the occurrence of new BCC by 20 % in skin cancer patients. CONCLUSIONS Targeted therapy with SHH inhibitors has improved the prognosis of locally advanced and metastatic BCC, albeit at the cost of a significant number of adverse events.
Collapse
Affiliation(s)
- M Heppt
- Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München (LMU), Frauenlobstr. 9-11, 80337, München, Deutschland
| | - T von Braunmühl
- Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München (LMU), Frauenlobstr. 9-11, 80337, München, Deutschland
| | - C Berking
- Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München (LMU), Frauenlobstr. 9-11, 80337, München, Deutschland.
| |
Collapse
|
360
|
Escudero-Góngora M, Fernández-Peñas P. FR - Nuevas indicaciones de nicotinamida en dermatología. ACTAS DERMO-SIFILIOGRAFICAS 2016; 107:777-778. [DOI: 10.1016/j.ad.2016.05.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Accepted: 05/29/2016] [Indexed: 01/18/2023] Open
|
361
|
Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) 2016; 9:2-10. [PMID: 26744449 DOI: 10.1158/1940-6207.capr-15-0406] [Citation(s) in RCA: 112] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
We have entered a transformative period in cancer prevention (including early detection). Remarkable progress in precision medicine and immune-oncology, driven by extraordinary recent advances in genome-wide sequencing, big-data analytics, blood-based technologies, and deep understanding of the tumor immune microenvironment (TME), has provided unprecedented possibilities to study the biology of premalignancy. The pace of research and discovery in precision medicine and immunoprevention has been astonishing and includes the following clinical firsts reported in 2015: driver mutations detected in circulating cell-free DNA in patients with premalignant lesions (lung); clonal hematopoiesis shown to be a premalignant state; molecular selection in chemoprevention randomized controlled trial (RCT; oral); striking efficacy in RCT of combination chemoprevention targeting signaling pathway alterations mechanistically linked to germline mutation (duodenum); molecular markers for early detection validated for lung cancer and showing promise for pancreatic, liver, and ovarian cancer. Identification of HPV as the essential cause of a major global cancer burden, including HPV16 as the single driver of an epidemic of oropharyngeal cancer in men, provides unique opportunities for the dissemination and implementation of public health interventions. Important to immunoprevention beyond viral vaccines, genetic drivers of premalignant progression were associated with increasing immunosuppressive TME; and Kras vaccine efficacy in pancreas genetically engineered mouse (GEM) model required an inhibitory adjuvant (Treg depletion). In addition to developing new (e.g., epigenetic) TME regulators, recent mechanistic studies of repurposed drugs (aspirin, metformin, and tamoxifen) have identified potent immune activity. Just as precision medicine and immune-oncology are revolutionizing cancer therapy, these approaches are transforming cancer prevention. Here, we set out a brief agenda for the immediate future of cancer prevention research (including a "Pre-Cancer Genome Atlas" or "PCGA"), which will involve the inter-related fields of precision medicine and immunoprevention - pivotal elements of a broader domain of personalized public health.
Collapse
Affiliation(s)
- Thomas W Kensler
- University of Pittsburgh, Pittsburgh, Pennsylvania and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
| | | | | | - Eva Szabo
- Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland
| | - J Jack Lee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Zigang Dong
- The Hormel Institute, University of Minnesota, Minneapolis, Minnesota
| | | | - William N Hait
- Janssen Research & Development, LLC, Raritan, New Jersey
| | | | - Nancy E Davidson
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
| | - Margaret Foti
- American Association for Cancer Research, Philadelphia, Pennsylvania
| | - Scott M Lippman
- Moores Cancer Center, University of California San Diego, La Jolla, California.
| |
Collapse
|
362
|
Hoorens I, Brochez L. Chemoprevention of basal cell carcinoma: reply from authors. Br J Dermatol 2016; 175:1404-1405. [PMID: 27716904 DOI: 10.1111/bjd.15055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- I Hoorens
- Department of Dermatology, University Hospital Ghent, De Pintelaan 185, 9000, Gent, Belgium
| | - L Brochez
- Department of Dermatology, University Hospital Ghent, De Pintelaan 185, 9000, Gent, Belgium
| |
Collapse
|
363
|
Ali F, Craythorne E, Al-Niaimi F. Chemoprevention of basal cell carcinoma. Br J Dermatol 2016; 175:1404. [DOI: 10.1111/bjd.14937] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- F.R. Ali
- Dermatological Surgery & Laser Unit; St John's Institute of Dermatology; St Thomas' Hospital; Westminster Bridge Road London SE1 7EH U.K
| | - E.E. Craythorne
- Dermatological Surgery & Laser Unit; St John's Institute of Dermatology; St Thomas' Hospital; Westminster Bridge Road London SE1 7EH U.K
| | - F. Al-Niaimi
- Dermatological Surgery & Laser Unit; St John's Institute of Dermatology; St Thomas' Hospital; Westminster Bridge Road London SE1 7EH U.K
| |
Collapse
|
364
|
Abstract
A well-established link between ultraviolet exposure and the carcinogenesis of keratinocyte carcinomas exists. Despite increased sun protection efforts, skin cancer remains the most common cancer in the USA. Numerous studies on the topic of chemoprevention investigate alternative topical, oral, and injectable agents to reduce skin cancer incidence in those at risk. Such agents include sunscreen, numerous vitamins and minerals, difluoromethylornithine, non-steroidal anti-inflammatory drugs, various peptides, field therapy, statins, and polyphenols. In this focused review, we discuss the risks and benefits of chemoprotective agents reported in clinical studies conducted in humans. We report several agents that may reduce skin cancer incidence in those at risk.
Collapse
|
365
|
Chen AC, Martin AJ, Dalziell RA, Halliday GM, Damian DL. Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial. Br J Dermatol 2016; 175:1363-1365. [PMID: 27062605 DOI: 10.1111/bjd.14648] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- A C Chen
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, 2050, Australia
| | - A J Martin
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
| | - R A Dalziell
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, 2050, Australia
| | - G M Halliday
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, 2050, Australia
| | - D L Damian
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, 2050, Australia.,Melanoma Institute Australia, North Sydney, Sydney, NSW, Australia
| |
Collapse
|
366
|
Nicotinamide Suppresses the DNA Damage Sensitivity of Saccharomyces cerevisiae Independently of Sirtuin Deacetylases. Genetics 2016; 204:569-579. [PMID: 27527516 DOI: 10.1534/genetics.116.193524] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Accepted: 08/15/2016] [Indexed: 11/18/2022] Open
Abstract
Nicotinamide is both a reaction product and an inhibitor of the conserved sirtuin family of deacetylases, which have been implicated in a broad range of cellular functions in eukaryotes from yeast to humans. Phenotypes observed following treatment with nicotinamide are most often assumed to stem from inhibition of one or more of these enzymes. Here, we used this small molecule to inhibit multiple sirtuins at once during treatment with DNA damaging agents in the Saccharomyces cerevisiae model system. Since sirtuins have been previously implicated in the DNA damage response, we were surprised to observe that nicotinamide actually increased the survival of yeast cells exposed to the DNA damage agent MMS. Remarkably, we found that enhanced resistance to MMS in the presence of nicotinamide was independent of all five yeast sirtuins. Enhanced resistance was also independent of the nicotinamide salvage pathway, which uses nicotinamide as a substrate to generate NAD+, and of a DNA damage-induced increase in the salvage enzyme Pnc1 Our data suggest a novel and unexpected function for nicotinamide that has broad implications for its use in the study of sirtuin biology across model systems.
Collapse
|
367
|
Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, Scolyer RA, Dhillon HM, Vardy JL, Bielski VA, Halliday GM, Damian DL. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol 2016; 175:1073-1075. [PMID: 27061568 DOI: 10.1111/bjd.14662] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- A C Chen
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia.,Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia
| | - A J Martin
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia
| | - R A Dalziell
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia
| | - C A McKenzie
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia
| | - P M Lowe
- Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.,Department of Dermatology, Royal Prince Alfred Hospital, Sydney, Australia
| | - J M Eris
- Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.,Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia
| | - R A Scolyer
- Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.,Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.,Melanoma Institute Australia, Sydney, Australia
| | - H M Dhillon
- Centre for Medical Psychology and Evidence-Based Decision-Making, University of Sydney, Sydney, Australia
| | - J L Vardy
- Centre for Medical Psychology and Evidence-Based Decision-Making, University of Sydney, Sydney, Australia.,Sydney Medical School, Concord Clinical School, University of Sydney, Sydney, Australia.,Concord Repatriation General Hospital, Sydney, Australia
| | - V A Bielski
- Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia
| | - G M Halliday
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia.,Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia
| | - D L Damian
- Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia. .,Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia. .,Melanoma Institute Australia, Sydney, Australia.
| |
Collapse
|
368
|
Sun WP, Zhai MZ, Li D, Zhou Y, Chen NN, Guo M, Zhou SS. Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels. Clin Nutr 2016; 36:1136-1142. [PMID: 27567458 DOI: 10.1016/j.clnu.2016.07.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Revised: 07/28/2016] [Accepted: 07/29/2016] [Indexed: 12/15/2022]
Abstract
AIM The present study was to compare the effects of nicotinic acid and nicotinamide on the plasma methyl donors, choline and betaine. METHODS Thirty adult subjects were randomly divided into three groups of equal size, and orally received purified water (C group), nicotinic acid (300 mg, NA group) or nicotinamide (300 mg, NM group). Plasma nicotinamide, N1-methylnicotinamide, homocysteine, betaine and choline levels before and 1.5-h and 3-h post-dosing, plasma normetanephrine and metanephrine concentrations at 3-h post-dosing, and the urinary excretion of N1-methyl-2-pyridone-5-carboxamide during the test period were examined. RESULTS The level of 3-h plasma nicotinamide, N1-methylnicotinamide, homocysteine, the urinary excretion of N1-methyl-2-pyridone-5-carboxamide and pulse pressure (PP) in the NM group was 221%, 3972%, 61%, 1728% and 21.2% higher than that of the control group (P < 0.01, except homocysteine and PP P < 0.05), while the 3-h plasma betaine, normetanephrine and metanephrine level in the NM group was 24.4%, 9.4% and 11.7% lower (P < 0.05, except betaine P < 0.01), without significant difference in choline levels. Similar but less pronounced changes were observed in the NA group, with a lower level of 3-h plasma N1-methylnicotinamide (1.90 ± 0.20 μmol/l vs. 3.62 ± 0.27 μmol/l, P < 0.01) and homocysteine (12.85 ± 1.39 μmol/l vs. 18.08 ± 1.02 μmol/l, P < 0.05) but a higher level of betaine (27.44 ± 0.71 μmol/l vs. 23.52 ± 0.61 μmol/l, P < 0.05) than that of the NM group. CONCLUSION The degradation of nicotinamide consumes more betaine than that of nicotinic acid at identical doses. This difference should be taken into consideration in niacin fortification.
Collapse
Affiliation(s)
- Wu-Ping Sun
- Institute of Basic Medical Sciences, Medical College, Dalian University, Dalian 116622, China; Okazaki Institute for Integrative Bioscience, National Institutes of Natural Sciences, Okazaki 444-8787, Japan
| | - Ming-Zhu Zhai
- Institute of Science and Technology Austria, Am Campus 1, Klosterneuburg 3400, Austria
| | - Da Li
- Institute of Basic Medical Sciences, Medical College, Dalian University, Dalian 116622, China; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, China
| | - Yiming Zhou
- Okazaki Institute for Integrative Bioscience, National Institutes of Natural Sciences, Okazaki 444-8787, Japan
| | - Na-Na Chen
- Institute of Basic Medical Sciences, Medical College, Dalian University, Dalian 116622, China
| | - Ming Guo
- College of Environmental and Chemical Engineering, Dalian University, Dalian 116622, China
| | - Shi-Sheng Zhou
- Institute of Basic Medical Sciences, Medical College, Dalian University, Dalian 116622, China.
| |
Collapse
|
369
|
Sanders K, Moran Z, Shi Z, Paul R, Greenlee H. Natural Products for Cancer Prevention: Clinical Update 2016. Semin Oncol Nurs 2016; 32:215-40. [PMID: 27539278 DOI: 10.1016/j.soncn.2016.06.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVES To present a clinical update of natural products for cancer prevention and provide oncology nurses with an evidence-based review of natural products for patient counseling and education. DATA SOURCES Clinical trials published in PubMed. CONCLUSION In the past 4 years since the publication of the original review there have been minimal changes in the conclusions of the published literature on the use of natural products for cancer prevention. To date, clinical trials have not demonstrated conclusive benefit of using natural products for cancer prevention, and current guidelines do not recommend their use. This review provides an update on published and ongoing trials and can serve as an updated resource for nurses. Evidence-based natural products databases can help nurses stay current with the scientific literature and be effective educators and health coaches for their patients, who can be influenced by marketing of unregulated products. IMPLICATIONS FOR NURSING PRACTICE Patients often discuss the use of natural products with nurses. Nurses have an opportunity to educate and coach patients in effective preventive lifestyle practices.
Collapse
|
370
|
Blazejczyk A, Switalska M, Chlopicki S, Marcinek A, Gebicki J, Nowak M, Nasulewicz-Goldeman A, Wietrzyk J. 1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2016; 35:110. [PMID: 27412454 PMCID: PMC4944260 DOI: 10.1186/s13046-016-0389-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Accepted: 06/28/2016] [Indexed: 12/16/2022]
Abstract
Background 1-methylnicotinamide (1-MNA), an endogenous metabolite of nicotinamide, has recently gained interest due to its anti-inflammatory and anti-thrombotic activities linked to the COX-2/PGI2 pathway. Given the previously reported anti-metastatic activity of prostacyclin (PGI2), we aimed to assess the effects of 1-MNA and its structurally related analog, 1,4-dimethylpyridine (1,4-DMP), in the prevention of cancer metastasis. Methods All the studies on the anti-tumor and anti-metastatic activity of 1-MNA and 1,4-DMP were conducted using the model of murine mammary gland cancer (4T1) transplanted either orthotopically or intravenously into female BALB/c mouse. Additionally, the effect of the investigated molecules on cancer cell-induced angiogenesis was estimated using the matrigel plug assay utilizing 4T1 cells as a source of pro-angiogenic factors. Results Neither 1-MNA nor 1,4-DMP, when given in a monotherapy of metastatic cancer, influenced the growth of 4T1 primary tumors transplanted orthotopically; however, both compounds tended to inhibit 4T1 metastases formation in lungs of mice that were orthotopically or intravenously inoculated with 4T1 or 4T1-luc2-tdTomato cells, respectively. Additionally, while 1-MNA enhanced tumor vasculature formation and markedly increased PGI2 generation, 1,4-DMP did not have such an effect. The anti-metastatic activity of 1-MNA and 1,4-DMP was further confirmed when both agents were applied with a cytostatic drug in a combined treatment of 4T1 murine mammary gland cancer what resulted in up to 80 % diminution of lung metastases formation. Conclusions The results of the studies presented below indicate that 1-MNA and its structural analog 1,4-DMP prevent metastasis and might be beneficially implemented into the treatment of metastatic breast cancer to ensure a comprehensive strategy of metastasis control. Electronic supplementary material The online version of this article (doi:10.1186/s13046-016-0389-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Agnieszka Blazejczyk
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland
| | - Marta Switalska
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland
| | - Stefan Chlopicki
- Chair of Pharmacology, Jagiellonian University, Medical College, Grzegórzecka 16, 31-531, Krakow, Poland.,Jagiellonian Center for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348, Krakow, Poland
| | - Andrzej Marcinek
- Lodz University of Technology, Zeromskiego 116, 90-924, Lodz, Poland
| | - Jerzy Gebicki
- Lodz University of Technology, Zeromskiego 116, 90-924, Lodz, Poland
| | - Marcin Nowak
- Wroclaw University of Environmental and Life Sciences, Norwida 31, 50-375, Wroclaw, Poland
| | - Anna Nasulewicz-Goldeman
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland
| | - Joanna Wietrzyk
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland.
| |
Collapse
|
371
|
McKenzie CA, Chen AC, Choy B, Fernández-Peñas P, Damian DL, Scolyer RA. Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. Pathology 2016; 48:395-7. [PMID: 27311865 DOI: 10.1016/j.pathol.2016.05.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Accepted: 05/19/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Catriona A McKenzie
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
| | - Andrew C Chen
- Dermatology and Bosch Institute, The University of Sydney at Royal Prince Alfred Hospital, Sydney, NSW, Australia
| | - Bonita Choy
- Dermatology, The University of Sydney at Westmead Hospital, Sydney, NSW, Australia
| | | | - Diona L Damian
- Dermatology and Bosch Institute, The University of Sydney at Royal Prince Alfred Hospital, Sydney, NSW, Australia; Melanoma Institute Australia, North Sydney, Sydney, NSW, Australia
| | - Richard A Scolyer
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Melanoma Institute Australia, North Sydney, Sydney, NSW, Australia; Discipline of Pathology, Sydney Medical School, The University of Sydney, NSW, Australia
| |
Collapse
|
372
|
Hoorens I, Vossaert K, Ongenae K, Brochez L. Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening. Br J Dermatol 2016; 174:1258-65. [PMID: 26872563 DOI: 10.1111/bjd.14477] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/04/2016] [Indexed: 11/29/2022]
Abstract
The incidence of basal cell carcinoma (BCC) has risen three- to fourfold over the last 30 years and is expected to continue to increase with ageing of the population. Although BCC has a good prognosis, it causes significant morbidity and has an important impact on the public health budget due to direct treatment costs. Based on the existing evidence, a systematic evaluation of the World Health Organization criteria was performed to determine whether earlier detection of BCC could reduce morbidity and cost. BCC slowly increases in size, with a median increase in diameter of 0·5 mm over 10 weeks. There is an important delay in diagnosis ranging from 19 to 25 months. In several studies BCC size was the main determinant of treatment cost, surgical complexity, reconstruction technique and the specific surgical procedure performed, such as Mohs micrographic surgery or surgical excision. One study showed that size also seems to affect the cost per treatment for other nonsurgical options. The use of vismodegib, an inhibitor of the hedgehog pathway, is confined to locally advanced or metastatic BCC. Delays in diagnosis and appropriate treatment are the most important underlying causes in the occurrence of giant BCC and/or BCC with metastasis. Although the latter represent only a very small fraction of all BCCs, the majority of them are located in the facial region. The available data point to a slow increase in the size of BCCs over time. Size is one of the major determinants in choice of treatment and the associated cost, especially for facial BCC. Therefore we conclude that current data support early detection and adequate management of BCCs on the face.
Collapse
Affiliation(s)
- I Hoorens
- Department of Dermatology, University Hospital Ghent, Ghent, Belgium
| | - K Vossaert
- Department of Dermatology, University Hospital Ghent, Ghent, Belgium.,Private Practice, Maldegem, Belgium
| | - K Ongenae
- Department of Dermatology, University Hospital Ghent, Ghent, Belgium
| | - L Brochez
- Department of Dermatology, University Hospital Ghent, Ghent, Belgium
| |
Collapse
|
373
|
Ali FR, Craythorne EE. Management of skin cancer in the elderly. J Geriatr Oncol 2016; 7:219-20. [DOI: 10.1016/j.jgo.2016.03.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2016] [Accepted: 03/29/2016] [Indexed: 10/21/2022]
|
374
|
Shchepin RV, Barskiy DA, Mikhaylov DM, Chekmenev EY. Efficient Synthesis of Nicotinamide-1-¹⁵N for Ultrafast NMR Hyperpolarization Using Parahydrogen. Bioconjug Chem 2016; 27:878-82. [PMID: 26999571 PMCID: PMC4843783 DOI: 10.1021/acs.bioconjchem.6b00148] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
![]()
Nicotinamide (a vitamin B3 amide) is one of the key
vitamins as well as a drug for treatment of M. tuberculosis, HIV, cancer, and other diseases. Here, an improved Zincke reaction
methodology is presented allowing for straightforward and scalable
synthesis of nicotinamide-1-15N with an excellent isotopic
purity (98%) and good yield (55%). 15N nuclear spin label
in nicotinamide-1-15N can be NMR hyperpolarized in seconds
using parahydrogen gas. NMR hyperpolarization using the process of
temporary conjugation between parahydrogen and to-be-hyperpolarized
biomolecule on hexacoordinate iridium complex via the Signal Amplification
By Reversible Exchange (SABRE) method significantly increases detection
sensitivity (e.g., >20 000-fold for nicotinamide-1-15N at 9.4 T) as has been shown by Theis T. et al. (J. Am.
Chem. Soc.2015, 137, 1404),
and hyperpolarized in this fashion, nicotinamide-1-15N
can be potentially used to probe metabolic processes in vivo in future
studies. Moreover, the presented synthetic methodology utilizes mild
reaction conditions, and therefore can also be potentially applied
to synthesis of a wide range of 15N-enriched N-heterocycles
that can be used as hyperpolarized contrast agents for future in vivo
molecular imaging studies.
Collapse
|
375
|
|
376
|
A Model to Predict the Risk of Keratinocyte Carcinomas. J Invest Dermatol 2016; 136:1247-1254. [PMID: 26908057 DOI: 10.1016/j.jid.2016.02.008] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 01/19/2016] [Accepted: 02/01/2016] [Indexed: 11/24/2022]
Abstract
Basal cell and squamous cell carcinomas of the skin are the commonest cancers in humans, yet no validated tools exist to estimate future risks of developing keratinocyte carcinomas. To develop a prediction tool, we used baseline data from a prospective cohort study (n = 38,726) in Queensland, Australia, and used data linkage to capture all surgically excised keratinocyte carcinomas arising within the cohort. Predictive factors were identified through stepwise logistic regression models. In secondary analyses, we derived separate models within strata of prior skin cancer history, age, and sex. The primary model included terms for 10 items. Factors with the strongest effects were >20 prior skin cancers excised (odds ratio 8.57, 95% confidence interval [95% CI] 6.73-10.91), >50 skin lesions destroyed (odds ratio 3.37, 95% CI 2.85-3.99), age ≥ 70 years (odds ratio 3.47, 95% CI 2.53-4.77), and fair skin color (odds ratio 1.75, 95% CI 1.42-2.15). Discrimination in the validation dataset was high (area under the receiver operator characteristic curve 0.80, 95% CI 0.79-0.81) and the model appeared well calibrated. Among those reporting no prior history of skin cancer, a similar model with 10 factors predicted keratinocyte carcinoma events with reasonable discrimination (area under the receiver operator characteristic curve 0.72, 95% CI 0.70-0.75). Algorithms using self-reported patient data have high accuracy for predicting risks of keratinocyte carcinomas.
Collapse
|
377
|
Scientific surgery. Br J Surg 2015. [DOI: 10.1002/bjs.10078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
378
|
|